Aims: the aim of our study was to investigate the diagnostic and prognostic value of SAA and its usability as a biomarker in patients with IPF. Methods: This study has been designed as a prospective, case-control study. Fifteen healthy individuals and 15 IPF patients. The demographic data and the measures from PFT, DLCO, laboratory tests of the patients included in the study were retrieved from IPF follow-up files. Results: The comparison of the IPF patient group with the group of healthy volunteers revealed significantly higher SAA values in IPF patients (p:0.005). A significant positive correlation was found between the patients' SAA and C-Reactive Protein (CRP) values. A negative significant correlation was found between the SAA values of the patients and the time to diagnosis (p<0.05). Despite the negative correlation between the SAA and FVC values of patients, no significant correlations were detected between these variables (p>0.05). This result suggests that SAA levels would be higher in newly or recently diagnosed . Conclusion: This study shows that SAA is significantly higher in IPF patients, suggesting that it will be a reliable biomarker feasible to predict the diagnosis. Future studies with larger patient groups ara needed.